What is Relmada Therapeutics Financial Strength?
Relmada Therapeutics has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Relmada Therapeutics Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Relmada Therapeutics has no long-term debt (1).
As of today, Relmada Therapeutics's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Relmada Therapeutics's Financial Strength
For the Biotechnology subindustry, Relmada Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relmada Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Relmada Therapeutics's Financial Strength falls into.
Relmada Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Relmada Therapeutics's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-26.83 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Relmada Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is
| Relmada Therapeutics had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Relmada Therapeutics Inc has no debt.
2. Debt to revenue ratio. The lower, the better.
Relmada Therapeutics's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Relmada Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relmada Therapeutics (Relmada Therapeutics) Business Description
Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Executives
| Cedric O'gorman |
officer: Chief Medical Officer |
C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134 |
| Fabiana Fedeli |
director |
C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134 |
| Sergio Traversa |
director, officer: Chief Executive Officer |
138 CANTERBURY LN, BLUE BELL PA 19422 |
| Paul Edward Kelly |
director |
300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022 |
| Charles J Casamento |
director |
99 BELBROOK WAY, ATHERTON CA 94027 |
| Maged Shenouda |
director |
305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011 |
| Thomas Wessel |
officer: EVP, Head of R&D |
15 SKYLINE DRIVE, HAWTHORNE NY 10532 |
| Eric Thomas Schmidt |
director |
C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| John Glasspool |
director |
C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
| Chuck Ence |
officer: Chief Financial Officer |
3000 S. UNIVERSITY BLVD., DENVER CO 80210 |
| Ottavio V. Vitolo |
officer: Chief Medical Officer |
71 WESTLAND AVENUE, NEWTON MA 02465 |
| Shreeram Agharkar |
director |
P.O BOX 2042, PRINCETON NJ 08543 |
| Sandesh Seth |
director |
300 E 93RD STREET, #20-B, NEW YORK NY 10128 |
| Lisa Nolan |
officer: Chief Business Officer |
36 ROCKLAND MILLS, ROCKLAND DE 19732 |
| Eliseo Oreste Salinas |
officer: President and CSO |
7707 GATEWAY BLVD, NEWARK CA 94560 |
Relmada Therapeutics (Relmada Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RLMD has been successfully added to your